Zobrazeno 1 - 10 of 23 pro vyhledávání: '"Jorge Gomez‐Miragaya"'
1
Akademický článek
RANK is a poor prognosis marker and a therapeutic target in ER‐negative postmenopausal breast cancer
Autor: Marina Ciscar, Eva M Trinidad, Gema Perez‐Chacon, Mansour Alsaleem, Maria Jimenez, Maria J Jimenez‐Santos, Hector Perez‐Montoyo, Adrian Sanz‐Moreno, Andrea Vethencourt, Michael Toss, Anna Petit, Maria T Soler‐Monso, Victor Lopez, Jorge Gomez‐Miragaya, Clara Gomez‐Aleza, Lacey E Dobrolecki, Michael T Lewis, Alejandra Bruna, Silvana Mouron, Miguel Quintela‐Fandino, Fatima Al‐Shahrour, Antonio Martinez‐Aranda, Angels Sierra, Andrew R Green, Emad Rakha, Eva Gonzalez‐Suarez
Publikováno v: EMBO Molecular Medicine, Vol 15, Iss 4, Pp 1-12 (2023)
Abstract Despite strong preclinical data, the therapeutic benefit of the RANKL inhibitor, denosumab, in breast cancer patients, beyond the bone, is unclear. Aiming to select patients who may benefit from denosumab, we hereby analyzed RANK and RANKL p
Externí odkaz: https://doaj.org/article/1a7e932a6a184ce6a384d4a58e43a0be
Zobrazit plný text záznamu
2
Akademický článek
RANK signaling increases after anti-HER2 therapy contributing to the emergence of resistance in HER2-positive breast cancer
Autor: Adrián Sanz-Moreno, Sonia Palomeras, Kim Pedersen, Beatriz Morancho, Tomas Pascual, Patricia Galván, Sandra Benítez, Jorge Gomez-Miragaya, Marina Ciscar, Maria Jimenez, Sonia Pernas, Anna Petit, María Teresa Soler-Monsó, Gemma Viñas, Mansour Alsaleem, Emad A. Rakha, Andrew R. Green, Patricia G. Santamaria, Celine Mulder, Simone Lemeer, Joaquin Arribas, Aleix Prat, Teresa Puig, Eva Gonzalez-Suarez
Publikováno v: Breast Cancer Research, Vol 23, Iss 1, Pp 1-18 (2021)
Abstract Background Around 15–20% of primary breast cancers are characterized by HER2 protein overexpression and/or HER2 gene amplification. Despite the successful development of anti-HER2 drugs, intrinsic and acquired resistance represents a major
Externí odkaz: https://doaj.org/article/30beb90cbbc444768fc569001a4484a0
Zobrazit plný text záznamu
3
Akademický článek
Tumor-initiating CD49f cells are a hallmark of chemoresistant triple negative breast cancer
Autor: Jorge Gomez-Miragaya, Eva González-Suárez
Publikováno v: Molecular & Cellular Oncology, Vol 4, Iss 4 (2017)
Taxanes are mainstay treatment of triple negative breast cancer (TNBC) patients but resistance often develops. Using TNBC patient-derived orthoxenografts (PDX) we have recently discovered that a CD49f+ chemoresistant population with tumor-initiating
Externí odkaz: https://doaj.org/article/9e0925ec87ed44fc950be5c6d32eb2bb
Zobrazit plný text záznamu
7
Data from RANK Signaling Blockade Reduces Breast Cancer Recurrence by Inducing Tumor Cell Differentiation
Autor: Eva González-Suárez, Lourdes Planelles, Miguel-Angel Pujana, Purificación Muñoz, William C. Dougall, Jordi Serra-Musach, Jorge Gomez-Miragaya, Alex Cordero, Eva M. Trinidad, Pasquale Pellegrini, Guillermo Yoldi
RANK expression is associated with poor prognosis in breast cancer even though its therapeutic potential remains unknown. RANKL and its receptor RANK are downstream effectors of the progesterone signaling pathway. However, RANK expression is enriched
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4683296f424049bd54c2ec9d3ccf6a32
https://doi.org/10.1158/0008-5472.c.6507533
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje